Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-3-10
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1755-3245
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
82
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4-6
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19221131-Administration, Oral, pubmed-meshheading:19221131-Animals, pubmed-meshheading:19221131-Cyclic GMP, pubmed-meshheading:19221131-Cyclic Nucleotide Phosphodiesterases, Type 5, pubmed-meshheading:19221131-Extracellular Matrix Proteins, pubmed-meshheading:19221131-Fibrosis, pubmed-meshheading:19221131-Hemodynamics, pubmed-meshheading:19221131-Humans, pubmed-meshheading:19221131-Hypertension, Pulmonary, pubmed-meshheading:19221131-Hypertrophy, Right Ventricular, pubmed-meshheading:19221131-Myocardium, pubmed-meshheading:19221131-Phosphodiesterase 5 Inhibitors, pubmed-meshheading:19221131-Phosphodiesterase Inhibitors, pubmed-meshheading:19221131-Piperazines, pubmed-meshheading:19221131-Purines, pubmed-meshheading:19221131-Rats, pubmed-meshheading:19221131-Sulfones, pubmed-meshheading:19221131-Ventricular Remodeling
pubmed:year
2009
pubmed:articleTitle
Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent?
pubmed:publicationType
Editorial, Comment